CLSD · As filed with the SEC
Clearside Biomedical balance sheet, by quarter
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 6,801,000 | 9,376,000 | 13,628,000 | 20,020,000 |
| Accounts receivable | 266,000 | 816,000 | 1,538,000 | 507,000 |
| Prepaid expenses | 1,187,000 | 1,580,000 | 721,000 | 734,000 |
| Other current assets | 0 | 13,000 | 77,000 | 13,000 |
| Total current assets | 8,254,000 | 11,785,000 | 15,964,000 | 21,274,000 |
| Property and equipment, net | 2,981,000 | 3,065,000 | 3,149,000 | 3,225,000 |
| Operating lease right-of-use asset | 376,000 | 452,000 | 525,000 | 597,000 |
| Other assets | 30,000 | 30,000 | 30,000 | 30,000 |
| Total assets | 11,641,000 | 15,332,000 | 19,668,000 | 25,126,000 |
| Liabilities and stockholders' deficit | ||||
| Current liabilities: | ||||
| Accounts payable (includes $491 to a related party as of December 31, 2024) | 796,000 | 1,129,000 | 1,914,000 | 1,452,000 |
| Accrued liabilities (includes $304 to a related party as of December 31, 2024) | 1,590,000 | 1,537,000 | 2,720,000 | 2,967,000 |
| Current portion of operating lease liabilities | 384,000 | 381,000 | 378,000 | 375,000 |
| Deferred revenue | — | — | — | 0 |
| Total current liabilities | 2,770,000 | 3,047,000 | 5,012,000 | 4,794,000 |
| Liability related to the sales of future royalties, net | 61,167,000 | 55,702,000 | 53,440,000 | 51,767,000 |
| Warrant liabilities | 1,192,000 | 4,765,000 | 6,485,000 | 6,692,000 |
| Operating lease liabilities | 62,000 | 152,000 | 241,000 | 328,000 |
| Other non-current liabilities | — | — | — | 400,000 |
| Other non-current liabilities | 400,000 | 400,000 | 400,000 | — |
| Total liabilities | 65,591,000 | 64,066,000 | 65,578,000 | 63,981,000 |
| Stockholders' deficit: | ||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at September 30, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value; 26,666,666 and 13,333,333 shares authorized at September 30, 2025 and December 31, 2024, respectively; 5,233,981 and 5,105,216 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 78,000 | 78,000 | 77,000 | 77,000 |
| Additional paid-in capital | 319,937,000 | 319,181,000 | 317,511,000 | 316,343,000 |
| Accumulated deficit | (373,965,000) | (367,993,000) | (363,498,000) | (355,275,000) |
| Total stockholders` deficit | (53,950,000) | (48,734,000) | (45,910,000) | (38,855,000) |
| Total liabilities and stockholders` deficit | 11,641,000 | 15,332,000 | 19,668,000 | 25,126,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.